christina dold

Employment

• Moderna Director and Research Program Leader, Infectious Diseases
  2022 - Present
• University of Oxford Oxford Vaccine Group
  2011 - 2022

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (68)

• Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines
  Vaccine 2023 DOI: 10.1016/j.vaccine.2023.04.012
  +Save
• Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
  Clinical and Experimental Immunology 2023 DOI: 10.1093/cei/uxad013
  +Save
• Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
  Clinical and Experimental Immunology 2023 DOI: 10.1093/cei/uxad003
  +Save
• Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
  Med 2023 DOI: 10.1016/j.medj.2023.02.004
  +Save
• Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
  Cell & Bioscience 2022 DOI: 10.1186/s13578-022-00809-3
  +Save
• Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19
  Christos P. Kotanidis, Cheng Xie, Donna Maria Alexander

  +97 more

  • Jonathan C. L. Rodrigues
  • Katie L. Burnham
  • Alexander J. Mentzer
  • Daniel O’Connor
  • Julian Charles Knight
  • +92 more
  The Lancet Digital Health 2022 DOI: 10.1016/s2589-7500(22)00132-7
  +Save
• Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers
  Clinical and Experimental Immunology 2022 DOI: 10.1093/cei/uxac042
  +Save
• Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
  JCI Insight 2022 DOI: 10.1172/jci.insight.156372
  +Save
• An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
  Natalie G. Marchevsky, Grace Li, Parvinder K. Aley +21 more
  eBioMedicine 2022 DOI: 10.1016/j.ebiom.2022.104128
  +Save
• Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation
  Vaccine 2022 DOI: 10.1016/j.vaccine.2022.04.085
  +Save
• Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial
  Vaccine 2022 DOI: 10.1016/j.vaccine.2022.05.032
  +Save
• Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity
  Frontiers in Immunology 2022 DOI: 10.3389/fimmu.2022.901372
  +Save
• Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner
  European Journal of Immunology 2022 DOI: 10.1002/eji.202149367
  +Save
• SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients
  Journal of the American Society of Nephrology 2022 DOI: 10.1681/asn.2021121587
  +Save
• Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity
  Journal of Infection 2022 DOI: 10.1016/j.jinf.2022.02.032
  +Save
• Divergent trajectories of antiviral memory after SARS-CoV-2 infection
  Adriana Tomić, Donal Skelly, Ane Ogbe +97 more
  Nature Communications 2022 DOI: 10.1038/s41467-022-28898-1
  +Save
• A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
  David Ahern, Zhichao Ai, Mark Andrew Ainsworth +97 more
  Cell 2022 DOI: 10.1016/j.cell.2022.01.012
  +Save
• Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial
  mSphere 2022 DOI: 10.1128/msphere.00674-21
  +Save
• SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
  Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou +97 more
  Cell 2022 DOI: 10.1016/j.cell.2021.12.046
  +Save
• An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
  Yanchun Peng, Suet Ling Felce, Danning Dong +63 more
  Nature Immunology 2022 DOI: 10.1038/s41590-021-01084-z
  +Save